Innate Pharma completes Phase 1 dose-escalation enrollment for Nectin-4 ADC IPH4502

Reuters2026/07/21 05:06

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Innate Pharma completed dose-escalation enrollment in its Phase 1 IPH4502-101 study of Nectin-4-targeting ADC IPH4502.
Preliminary results have not been presented yet; a first readout is expected by year-end, covering 76 patients.
Early findings to date show a favorable safety profile, with limited blood-related toxicity.
Initial tumor responses were observed in heavily pre-treated patients, including urothelial cancer after enfortumab vedotin, NSCLC, and HNSCC.
The upcoming dataset is expected to guide dose optimization decisions and shape next steps in selected tumor types.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innate Pharma SA published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Innate Pharma completes Phase 1 dose-escalation enrollment for Nectin-4 ADC IPH4502

You may also like

Crypto prices